SCHEMBL6281461

SCHEMBL6281461

CC(O)[SiH2]C(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
ADRA2C P18825 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ADRA2A P08913 1/20 0.46
HIF1A Q16665 1/20 0.46
ALDH1A1 P00352 2/20 0.45
SLC6A4 P31645 1/20 0.44
TSHR P16473 2/20 0.43
CHRM2 P08172 1/20 0.43
ADRA1A P35348 1/20 0.43
RGS12 O14924 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
NFKB1 P19838 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774509 0.79 DPP4 (0.45) LMNASLC6A4TSHRCYP2D6HTR2A
SCHEMBL3454932 0.76 TAAR1 (0.38) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL8681720 0.76 SRC (0.46) LMNAKDM4EHIF1AALDH1A1CYP3A4
SCHEMBL5596091 0.71 LMNA (0.42) LMNAADRA2CKDM4EADRA2AHIF1A
Phenyl Ethanol SCHEMBL8075664 0.71 LMNA (0.56) LMNAADRA2CKDM4EADRA2AHIF1A
Phenyl Ethanol SCHEMBL32685157 0.71
Phenyl Ethanol SCHEMBL27653400 0.71 LMNA (0.56) LMNAADRA2CKDM4EADRA2AHIF1A
Phenyl Ethanol SCHEMBL7144 0.71
Phenyl Ethanol SCHEMBL2164 0.71
Phenyl Ethanol SCHEMBL2165 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6870039-B2 Synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2005-03-22 US disclosed
US-20040063925-A1 Synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2004-04-01 US disclosed
US-6646114-B2 Especially phosphorothioate oligonucleotides, and to intermediates used in that process; solution phase synthesis having improved efficiencies and enhanced convenience and cost ISIS PHARMACEUTICALS, INC. 2003-11-11 US disclosed
US-20030069412-A1 Synthesis of oligonucleotides RAVIKUMAR VASULINGA (US) 2003-04-10 US disclosed
US-6486312-B2 LIQUID PHASE BIOSYNTHESIS ISIS PHARMACEUTICALS, INC. 2002-11-26 US disclosed
US-6294664-B1 PREPARING OLIGONUCLEOTIDE BLOCKS HAVING COMMON SUBSEQUENCES, PHOSPITYLATING, AND PERFORMING SOLID PHASE SYNTHESIS (SPS) TO FORM TARGET OLIGONUCLEOTIDES WHEREIN THE SYNTHONS USED IN SPS COMPRISE PHOSPHITYLATED OLIGONUCLEOTIDE BLOCKS ISIS PHARMACEUTICALS, INC. 2001-09-25 US disclosed
US-20010018510-A1 Synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2001-08-30 US disclosed
US-6211350-B1 REACTING SYNTHON WITH TWO NUCLEOSIDE UNITS AND WITH SYNTHON HAVING ONE NUCLEOSIDE UNIT TO OBTAIN OLIGONUCLEOTIDE CONTAINING PHOSPHOROTHIOATE GROUPS ISIS PHARMACEUTICALS, INC. 2001-04-03 US disclosed
US-6124450-A Processes and intermediates for phosphorous-containing covalent linkages ISIS PHARMACEUTICALS, INC. (US) 2000-09-26 US disclosed
US-6001982-A Synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 1999-12-14 US disclosed
EP-0766688-A4 SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 1998-12-30 EP disclosed
US-5847106-A Monomeric and dimeric nucleosides with silyl-containing diamino phosphorous linkages ISIS PHARMACEUTICALS INC. (US) 1998-12-08 US disclosed
EP-0766688-A1 SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1997-04-09 EP disclosed
US-5614621-A Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents ISIS PHARMACEUTICALS, INC. (US) 1997-03-25 US disclosed
US-5571902-A OLIGOMERIZATION IN THE PRESENCE OF TETRAZOLE COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1996-11-05 US disclosed
EP-0711301-A4 PROCESSES AND INTERMEDIATES FOR PHOSPHOROUS-CONTAINING COVALENT LINKAGES ISIS PHARMACEUTICALS INC (US) 1996-07-17 EP disclosed
EP-0711301-A1 PROCESSES AND INTERMEDIATES FOR PHOSPHOROUS-CONTAINING COVALENT LINKAGES ISIS PHARMACEUTICALS, INC. (US) 1996-05-15 EP disclosed
WO-1995032980-A1 SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1995-12-07 WO disclosed
WO-1995004065-A1 PROCESSES AND INTERMEDIATES FOR PHOSPHOROUS-CONTAINING COVALENT LINKAGES ISIS PHARMACEUTICALS, INC. (US) 1995-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063925-A1 Synthesis of oligonucleotides RNGTT, POLRMT, POLI LMNA 1993/4885ADRA2C 4573/4885KDM4E 3995/4885
US-20030069412-A1 Synthesis of oligonucleotides RNGTT, POLRMT, POLI LMNA 1993/4885ADRA2C 4573/4885KDM4E 3995/4885
US-20010018510-A1 Synthesis of oligonucleotides RNGTT, POLRMT, POLI LMNA 1993/4885ADRA2C 4573/4885KDM4E 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.